Campbell & CO Investment Adviser LLC Purchases Shares of 37,255 ClearPoint Neuro, Inc. $CLPT

Campbell & CO Investment Adviser LLC purchased a new stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 37,255 shares of the company’s stock, valued at approximately $445,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of CLPT. Millennium Management LLC boosted its stake in ClearPoint Neuro by 156.3% during the first quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after buying an additional 452,043 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in ClearPoint Neuro by 98.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after acquiring an additional 127,823 shares during the last quarter. Lane Generational LLC lifted its holdings in ClearPoint Neuro by 53.5% in the 1st quarter. Lane Generational LLC now owns 242,045 shares of the company’s stock valued at $2,878,000 after acquiring an additional 84,350 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of ClearPoint Neuro during the 1st quarter valued at about $429,000. Finally, Dauntless Investment Group LLC acquired a new position in shares of ClearPoint Neuro in the 1st quarter worth approximately $166,000. Institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Price Performance

Shares of NASDAQ:CLPT opened at $15.43 on Friday. The company has a market cap of $438.57 million, a P/E ratio of -19.05 and a beta of 1.28. The company’s fifty day moving average is $19.89 and its two-hundred day moving average is $14.61. The company has a quick ratio of 6.45, a current ratio of 7.30 and a debt-to-equity ratio of 1.46. ClearPoint Neuro, Inc. has a 12-month low of $9.76 and a 12-month high of $30.10.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%.The business had revenue of $5.36 million during the quarter, compared to analysts’ expectations of $9.60 million. ClearPoint Neuro has set its FY 2025 guidance at EPS. Equities analysts expect that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ClearPoint Neuro news, CEO Joseph Burnett sold 26,463 shares of the stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $26.98, for a total value of $713,971.74. Following the completion of the sale, the chief executive officer owned 217,059 shares in the company, valued at $5,856,251.82. This represents a 10.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on CLPT. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, October 8th. Stifel Nicolaus upped their price target on ClearPoint Neuro from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, Wall Street Zen downgraded ClearPoint Neuro from a “hold” rating to a “sell” rating in a research report on Saturday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.67.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.